JP6902803B2 - Antifungal composition - Google Patents
Antifungal composition Download PDFInfo
- Publication number
- JP6902803B2 JP6902803B2 JP2019224533A JP2019224533A JP6902803B2 JP 6902803 B2 JP6902803 B2 JP 6902803B2 JP 2019224533 A JP2019224533 A JP 2019224533A JP 2019224533 A JP2019224533 A JP 2019224533A JP 6902803 B2 JP6902803 B2 JP 6902803B2
- Authority
- JP
- Japan
- Prior art keywords
- antifungal
- holotoxin
- fibroin
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012871 anti-fungal composition Substances 0.000 title description 14
- 108010022355 Fibroins Proteins 0.000 claims description 35
- 229930186900 holotoxin Natural products 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 29
- 208000002474 Tinea Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 10
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 8
- 238000011109 contamination Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 3
- 230000002160 anti-trichophyton Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 description 34
- 239000003429 antifungal agent Substances 0.000 description 29
- 230000000843 anti-fungal effect Effects 0.000 description 24
- 238000000605 extraction Methods 0.000 description 10
- 241000233866 Fungi Species 0.000 description 9
- 241000251511 Holothuroidea Species 0.000 description 8
- 230000002538 fungal effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 201000010618 Tinea cruris Diseases 0.000 description 5
- 208000024386 fungal infectious disease Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 208000007712 Tinea Versicolor Diseases 0.000 description 3
- 206010056131 Tinea versicolour Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 201000009862 superficial mycosis Diseases 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 206010018143 Genital candidiasis Diseases 0.000 description 1
- QIFOTGBMWFMXRC-UHFFFAOYSA-N Holotoxin A Natural products OC1C(OC)C(O)C(CO)OC1OC1C(O)C(OC2C(OCC(C2O)OC2C(C(O)C(OC3C(C(O)C(O)CO3)O)C(C)O2)O)OC2C(C3C(C=4C(C5(CC(=O)C6C5(C(OC6(CCCC(C)(C)O)C)=O)CC=4)C)CC3)(C)CC2)(C)C)OC(CO)C1O QIFOTGBMWFMXRC-UHFFFAOYSA-N 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001522839 Saturnia japonica Species 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- BIHNZKYXOTXXSP-GCBHNEMQSA-N holotoxin a Chemical compound O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](OC)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@@H](C)O3)O)[C@H](OC3C(C4[C@](C=5C([C@@]6(CC(=O)[C@H]7C6(C(O[C@]7(CCCC(C)=C)C)=O)CC=5)C)CC4)(C)CC3)(C)C)OC2)O)O[C@H](CO)[C@H]1O BIHNZKYXOTXXSP-GCBHNEMQSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、ホロトキシンの抗真菌作用を増強できる抗真菌剤組成物に関する。 The present invention relates to an antifungal agent composition capable of enhancing the antifungal action of holotoxin.
カビや酵母等の真菌は広く自然界に分布しているが、一部の真菌はヒトに対して病原性を示し、水虫・タムシ等の白癬、皮膚カンジダ症、癜風、マラセチア毛包炎、慢性粘膜皮膚カンジダ症、口腔カンジダ症、外陰カンジダ症等の真菌症を引き起こす原因になっている。更に、真菌は、食物、衣類、浴槽の壁等に付着し、劣化、腐敗、悪臭等を引き起こす原因にもなっている。このような現状に対し、従来、様々な抗真菌剤が真菌の制御のために使用されている。 Fungi such as mold and yeast are widely distributed in nature, but some fungi are pathogenic to humans, such as athlete's foot and ringworm, tinea versicolor, tinea versicolor, malacetia folliculitis, and chronic It is a cause of mycoses such as mucocutaneous candidiasis, oral candidiasis, and tinea versicolor. Furthermore, fungi adhere to food, clothing, bathtub walls, etc., and cause deterioration, putrefaction, foul odors, and the like. In response to this situation, various antifungal agents have been conventionally used for controlling fungi.
皮膚真菌症は抗真菌剤による治療によって一旦症状が治まっても、再発し易いことが知られている。また、生活環境で汚染の問題となる真菌についても、抗真菌剤によって活動を抑制できても、時間の経過と共に活動を開始し始めることがある。そのため、抗真菌作用を増強させた抗真菌剤組成物の開発が望まれている。 It is known that dermatomycosis is likely to recur even once the symptoms have been cured by treatment with antifungal agents. In addition, even if the activity of fungi, which poses a problem of pollution in the living environment, can be suppressed by antifungal agents, the activity may start over time. Therefore, it is desired to develop an antifungal agent composition having an enhanced antifungal action.
一方、従来、ナマコより分離されたサポニン系抗真菌剤であるホロトキシンは、白癬菌に対して高い抗真菌作用を示すことが知られており、白癬の治療薬として実用化されている。また、ホロトキシンは、抗真菌スペクトルが広く、白癬菌だけでなく、クロカワカビ、黒コウジカビ、青カビ等の広範な真菌に対しても抗真菌作用を発揮でき、家庭用の防カビ剤としても有効であることが報告されている（特許文献１参照）。 On the other hand, conventionally, horotoxin, which is a saponin-based antifungal agent isolated from sea cucumber, is known to exhibit a high antifungal action against ringworm, and has been put into practical use as a therapeutic agent for ringworm. In addition, holotoxin has a wide antifungal spectrum and can exert an antifungal effect not only on ringworm but also on a wide range of fungi such as black mold, black aspergillus, and blue mold, and is also effective as a household fungicide. It has been reported (see Patent Document 1).
しかしながら、従来、ホロトキシンの抗真菌作用を増強させるための製剤技術については、十分な検討が行われていない。 However, conventionally, a pharmaceutical technique for enhancing the antifungal action of holotoxin has not been sufficiently studied.
本発明の目的は、ホロトキシンの抗真菌作用を増強できる抗真菌剤組成物を提供することである。 An object of the present invention is to provide an antifungal agent composition capable of enhancing the antifungal action of holotoxin.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、ホロトキシンと共に、それ自体は抗真菌作用を有していないフィブロインを併用することによって、ホロトキシンの抗真菌作用を飛躍的に向上させ得ることを見出した。本発明は、かかる知見に基づいて更に検討を重ねることにより完成したものである。 The present inventor has made diligent studies to solve the above problems, and found that the antifungal activity of holotoxin is dramatically improved by using fibroin, which does not have an antifungal activity by itself, in combination with holotoxin. Found to get. The present invention has been completed by further studies based on such findings.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． ホロトキシン、及びフィブロインを含有する、抗真菌剤組成物。
項２． ホロトキシン１００重量部当たり、フィブロインを１〜１００００重量部含む、項１に記載の抗真菌剤組成物。
項３． 外用医薬品、化粧料、又は皮膚洗浄料である、項１又は２に記載の抗真菌剤組成物。
項４． 真菌症の予防又は治療に使用される、項３に記載の抗真菌剤組成物。
項５． 住環境における真菌汚染の予防又は改善に使用される、項１又は２に記載の抗真菌剤組成物。
That is, the present invention provides the inventions of the following aspects.
Item 1. An antifungal composition containing holotoxin and fibroin.
Item 2. Item 2. The antifungal composition according to Item 1, which contains 1 to 10000 parts by weight of fibroin per 100 parts by weight of holotoxin.
Item 3. Item 2. The antifungal composition according to Item 1 or 2, which is an external medicine, a cosmetic, or a skin cleanser.
Item 4. Item 3. The antifungal composition according to Item 3, which is used for the prevention or treatment of mycosis.
Item 5. Item 2. The antifungal composition according to Item 1 or 2, which is used for preventing or improving fungal contamination in a living environment.
本発明の抗真菌医薬組成物によれば、ホロトキシンの抗真菌作用が飛躍的に増強されているので、真菌症の予防又は治療や、住環境における真菌汚染の予防又は改善に有効である。 According to the antifungal pharmaceutical composition of the present invention, since the antifungal action of holotoxin is dramatically enhanced, it is effective for prevention or treatment of mycosis and prevention or improvement of fungal contamination in the living environment.
本発明の抗真菌剤組成物は、ホロトキシン、及びフィブロインを含有することを特徴とする。以下、本発明の抗真菌剤組成物について詳述する。 The antifungal composition of the present invention is characterized by containing holotoxin and fibroin. Hereinafter, the antifungal agent composition of the present invention will be described in detail.
［ホロトキシン］
本発明の抗真菌剤組成物は、抗真菌成分としてホロトキシンを含有する。ホロトキシンは、ナマコに含まれているステロイド系のサポニンである。
[Horotoxin]
The antifungal composition of the present invention contains holotoxin as an antifungal component. Holotoxin is a steroidal saponin contained in sea cucumber.
ホロトキシンには、ホロトキシンＡ、ホロトキシンＢ、及びホロトキシンＣの３つの構造が知られているが、本発明では、ホロトキシンとして1種のものを単独で使用してもよく、２種以上を組み合わせて使用してもよい。 Three structures of holotoxin A, holotoxin B, and holotoxin C are known as holotoxin, but in the present invention, one type of holotoxin may be used alone, or two or more types may be used in combination. You may.
また、本発明で使用するホロトキシンは、精製物であってもよいが、粗精製物や抽出物であってもよい。 Further, the holotoxin used in the present invention may be a purified product, but may be a crude product or an extract.
ホロトキシンは、ナマコの体壁組織を抽出処理することにより得ることができる。以下、ナマコの体壁組織からホロトキシンを得る手法について説明する。 Holotoxin can be obtained by extracting and treating the body wall tissue of sea cucumber. Hereinafter, a method for obtaining horotoxin from the body wall tissue of sea cucumber will be described.
抽出原料として使用されるナマコの体壁組織は、未乾燥物又は乾燥物のいずれであってもよいが、乾燥物であることが好ましい。 The body wall structure of sea cucumber used as an extraction raw material may be either an undried product or a dried product, but is preferably a dried product.
また、抽出原料として使用されるナマコの体壁組織は、抽出効率を高めるために、細切又は粉砕された物であることが好ましい。抽出溶媒としては、水、有機溶媒、及びこれらの混合溶媒が挙げられる。有機溶媒としては、具体的には、炭素数１〜５の1価アルコール（エタノール、メタノール、プロパノール、イソプロパノール等）、炭素数２〜５の多価アルコール（グリセリン、イソプロピレングリコール、プロピレングリコール及び１，３−ブチレングリコール等）、エステル（酢酸メチル等）、ケトン（アセトン等）等が挙げられる。これらの抽出溶媒の中でも、安全性及び有効成分の抽出効率の点から、好ましくは、炭素数１〜５の1価アルコール又は炭素数１〜５の1価アルコールと水の混合溶媒が挙げられる。 Further, the body wall structure of sea cucumber used as an extraction raw material is preferably shredded or crushed in order to improve the extraction efficiency. Examples of the extraction solvent include water, an organic solvent, and a mixed solvent thereof. Specific examples of the organic solvent include monohydric alcohols having 1 to 5 carbon atoms (ethanol, methanol, propanol, isopropanol, etc.), polyhydric alcohols having 2 to 5 carbon atoms (glycerin, isopropylene glycol, propylene glycol, and 1). , 3-butylene glycol, etc.), esters (methyl acetate, etc.), ketones (acetone, etc.) and the like. Among these extraction solvents, a monohydric alcohol having 1 to 5 carbon atoms or a mixed solvent of a monohydric alcohol having 1 to 5 carbon atoms and water is preferable from the viewpoint of safety and extraction efficiency of the active ingredient.
抽出処理は、抽出溶媒中に、ナマコの体壁組織を浸漬又は還流させて行えばよい。 The extraction treatment may be carried out by immersing or refluxing the body wall tissue of sea cucumber in the extraction solvent.
抽出処理後に固液分離により固形物を除去することにより、ホロトキシンを含む抽出液が得られる。得られた抽出液は、そのまま又は濃縮して液状の抽出物として使用してもよく、また、スプレードライ、減圧濃縮乾燥、凍結乾燥等の乾燥処理に供することにより、固形状の抽出物として使用してもよい。 By removing the solid matter by solid-liquid separation after the extraction treatment, an extract containing holotoxin can be obtained. The obtained extract may be used as it is or after being concentrated and used as a liquid extract, or may be used as a solid extract by being subjected to a drying treatment such as spray drying, concentrated drying under reduced pressure, or freeze drying. You may.
また、得られた抽出物を、濾過処理；ポリスチレンゲル（ポリスチレン・ジビニルベンゼン共重合体等）、イオン交換樹脂、活性炭等の担体を充填したカラムを用いた各種クロマトグラフィー等の精製処理に供することにより、ホロトキシンの粗精製品又は精製品を得ることができる。 In addition, the obtained extract is subjected to filtration treatment; purification treatment such as various chromatography using a column packed with a carrier such as polystyrene gel (polystyrene / divinylbenzene copolymer, etc.), ion exchange resin, activated carbon, etc. Therefore, a crude product or a refined product of holotoxin can be obtained.
本発明の抗真菌剤組成物におけるホロトキシンの含有量については、抗真菌剤組成物の形態や用途等に応じて適宜設定すればよいが、例えば、０．００１重量％以上、好ましくは０．００１〜０．１重量％、より好ましくは０．００５〜０．５重量％が挙げられる。 The content of holotoxin in the antifungal agent composition of the present invention may be appropriately set according to the form and use of the antifungal agent composition, and is, for example, 0.001% by weight or more, preferably 0.001. ~ 0.1% by weight, more preferably 0.005 to 0.5% by weight.
［フィブロイン］
本発明の抗真菌剤組成物は、ホロトキシンと共にフィブロインを含有する。フィブロイン自体には抗真菌作用がないが、ホロトキシンとフィブロインを併用することにより、ホロトキシンの抗真菌作用を飛躍的に向上させることが可能になる。
[Fibroin]
The antifungal composition of the present invention contains fibroin together with holotoxin. Fibroin itself has no antifungal activity, but the combined use of holotoxin and fibroin makes it possible to dramatically improve the antifungal activity of holotoxin.
フィブロインは、繭に含まれるシルクタンパク質の１種である。本発明で使用されるフィブロインの由来については、特に制限されないが、例えば、家蚕が産生するシルクタンパク質；テンサン、サクサン、タタールサン、シンジュサン等の野蚕等が産生するシルクタンパク質等のシルクタンパク質由来のものが挙げられる。本発明で使用するフィブロインは、１種の由来のものを単独で使用してもよく、また２種以上の由来のものを組み合わせて使用してもよい。これらの中でも、好ましくは、家蚕由来のフィブロインが挙げられる。 Fibroin is a type of silk protein contained in cocoons. The origin of fibroin used in the present invention is not particularly limited, but is, for example, derived from silk protein produced by domestic silk moth; silk protein such as silk protein produced by wild silk moth such as silk moth, tussah, tatarsan, and silk moth. Things can be mentioned. As the fibroin used in the present invention, one derived from one kind may be used alone, or one derived from two or more kinds may be used in combination. Among these, fibroin derived from silk moth is preferable.
本発明で使用されるフィブロインは、繭から抽出処理することにより得られたものであってもよく、また遺伝子工学的手法により得られたものであってもよい。 The fibroin used in the present invention may be obtained by extraction treatment from a cocoon, or may be obtained by a genetic engineering method.
また、本発明で使用されるフィブロインの好適な一例として、フィブロインを含む水溶液を予備凍結した後に凍結乾燥することにより得られるフィブロイン成形物を粉末化したものが挙げられる。このようなフィブロイン成形物の粉末を使用することにより、ホロトキシンの抗真菌作用をより一層効果的に増強することが可能になる。 Further, as a preferable example of the fibroin used in the present invention, there is a pulverized fibroin molded product obtained by pre-freezing an aqueous solution containing fibroin and then freeze-drying. By using the powder of such a fibroin molded product, it becomes possible to more effectively enhance the antifungal action of holotoxin.
本発明の抗真菌剤組成物において、ホロトキシンとフィブロインの比率としては、例えば、ホロトキシン１００重量部当たり、フィブロインが１〜１００００重量部、好ましくは１０〜１０００重量部、より好ましくは５０〜５００重量部が挙げられる。 In the antifungal composition of the present invention, the ratio of holotoxin to fibroin is, for example, 1 to 10000 parts by weight, preferably 10 to 1000 parts by weight, more preferably 50 to 500 parts by weight of fibroin per 100 parts by weight of holotoxin. Can be mentioned.
また、本発明の抗真菌剤組成物におけるフィブロインの含有量については、ホロトキシンとフィブロインの比率、抗真菌剤組成物の形態や用途等を勘案して適宜設定すればよいが、例えば、例えば、０．００１重量％以上、好ましくは０．００１〜０．１重量％、より好ましくは０．００５〜０．５重量％が挙げられる。 The content of fibroin in the antifungal agent composition of the present invention may be appropriately set in consideration of the ratio of holotoxin and fibroin, the form and use of the antifungal agent composition, and the like. .001% by weight or more, preferably 0.001 to 0.1% by weight, more preferably 0.005 to 0.5% by weight.
［その他の成分］
本発明の抗真菌剤組成物は、必要に応じて、他の生理活性成分が含まれていてもよい。このような生理活性成分としては、例えば、ホロトキシン以外の抗真菌剤、殺菌剤、抗菌剤、ステロイド剤、抗ヒスタミン剤、局所麻酔剤、抗炎症剤、鎮痒剤、皮膚保護剤、血行促進剤等が挙げられる。これらの薬効成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
[Other ingredients]
The antifungal composition of the present invention may contain other physiologically active ingredients, if necessary. Examples of such physiologically active ingredients include antifungal agents other than holotoxin, bactericides, antibacterial agents, steroid agents, antihistamines, local anesthetics, anti-inflammatory agents, antipruritic agents, skin protectants, blood circulation promoters and the like. Be done. These medicinal ingredients may be used alone or in combination of two or more.
また、本発明の抗真菌剤組成物は、所望の剤型に調製するための他の添加成分が含まれていてもよい。このような添加成分としては、例えば、水、緩衝液、１価低級アルコール、多価アルコール等の水性基剤；動物油、植物油、鉱物油、ワックス、ロウ、エステル油、脂肪酸アルキルエステル、高級脂肪酸、１価高級アルコール、シリコーンオイル、コレステロール等の油分；界面活性剤、可溶化剤、油性基剤、増粘剤、キレート剤、防腐剤、保存剤、酸化防止剤、安定化剤、香料、着色料等が挙げられる。 In addition, the antifungal composition of the present invention may contain other additive components for preparing a desired dosage form. Such additive components include, for example, aqueous bases such as water, buffers, monohydric lower alcohols, polyhydric alcohols; animal oils, vegetable oils, mineral oils, waxes, waxes, ester oils, fatty acid alkyl esters, higher fatty acids, etc. Oils such as monohydric higher alcohols, silicone oils, cholesterol; surfactants, solubilizers, oily bases, thickeners, chelating agents, preservatives, preservatives, antioxidants, stabilizers, fragrances, coloring agents And so on.
［剤型］
本発明の抗真菌剤組成物の剤型については、特に制限されず、液状、固形状、半固形状（クリーム状、ゲル状、軟膏状、ペースト状）等のいずれであってもよい。
[Dosage form]
The dosage form of the antifungal agent composition of the present invention is not particularly limited, and may be liquid, solid, semi-solid (cream, gel, ointment, paste) or the like.
［製剤形態・用途］
本発明の抗真菌剤組成物は、真菌に対して広い抗真菌スペクトルを示す。本発明の抗真菌剤組成物の適用対象となる真菌については、特に制限されないが、例えば、白癬菌、カンジダ菌、マラセチア、クリプトコッカス属真菌、クロカワカビ、黒コウジカビ、青カビ等が挙げられる。
[Formation / use]
The antifungal composition of the present invention exhibits a broad antifungal spectrum against fungi. The fungus to which the antifungal agent composition of the present invention is applied is not particularly limited, and examples thereof include Trichophyton, Candida, Malassezia, Cryptococcus fungi, Black Aspergillus, Black Aspergillus, and Blue mold.
本発明の抗真菌剤組成物は、優れた抗真菌作用を発揮できるので、真菌症の予防又は治療、住環境における真菌汚染の予防又は改善等の用途に使用できる。 Since the antifungal agent composition of the present invention can exert an excellent antifungal action, it can be used for the prevention or treatment of mycosis, the prevention or improvement of fungal contamination in the living environment, and the like.
本発明の抗真菌剤組成物を真菌症の予防又は治療用途に使用する場合、予防又は治療対象となる真菌症としては、例えば、白癬（水虫、タムシ、爪白癬、体部白癬、股部白癬等）、癜風、マラセチア毛包炎、口腔カンジダ症、外陰部カンジダ症、膣カンジダ症、皮膚カンジダ症等の表在性真菌症；皮膚クリプトコッカス症、深在性白癬等の深在性真菌症が挙げられる。本発明の抗真菌剤組成物は、真菌症の中でも、表在性真菌症、特に白癬に対して、優れた予防又は治療効果を奏することができるので、表在性真菌症の予防又は治療剤、特に白癬の予防又は治療剤として好適に使用される。 When the antifungal agent composition of the present invention is used for the prevention or treatment of mycosis, the mycosis to be prevented or treated includes, for example, tinea cruris (water bug, worm, tinea cruris, tinea cruris, tinea cruris, tinea cruris). Etc.), epilepsy, malacetia folliculitis, oral candidiasis, genital candidiasis, vaginal candidiasis, cutaneous candidiasis, etc. Can be mentioned. Since the antifungal agent composition of the present invention can exert an excellent preventive or therapeutic effect on superficial mycosis, particularly ringworm, among mycoses, a prophylactic or therapeutic agent for superficial mycosis. , Especially preferably used as a prophylactic or therapeutic agent for ringworm.
本発明の抗真菌剤組成物を真菌症の予防又は治療用途に使用する場合、本発明の抗真菌剤組成物を、ジェル剤、乳液剤、液剤、クリーム剤、ローション剤、パップ剤、貼付剤、リニメント剤、エアゾール剤、軟膏剤、パック剤等の外用医薬品；軟膏、クリーム、乳液、化粧水、ローション、パック、ゲル等の化粧料；ボディーシャンプー、ヘアシャンプー、リンス等の皮膚洗浄料等として提供すればよい。 When the antifungal agent composition of the present invention is used for the prevention or treatment of fungal diseases, the antifungal agent composition of the present invention may be used as a gel, a milky lotion, a liquid, a cream, a lotion, a poultice, or a patch. , Liniment, aerosol, ointment, pack, etc.; cosmetics such as ointment, cream, milky lotion, lotion, pack, gel; body shampoo, hair shampoo, rinse, etc. You can provide it.
また、本発明の抗真菌剤組成物を住環境における真菌汚染の予防又は改善用途に使用する場合、真菌汚染が生じ易い部位、例えば、台所、浴室、トイレ、洗面台等の壁面や床面；排水口、洗濯槽、衣類、カーテン、バスマット、エアコンの内部やフィルター等に対して、真菌汚染が生じる前、又は真菌汚染が生じた後に、本発明の抗真菌剤組成物を、塗布、噴霧等によってすることにより使用すればよい。本発明の抗真菌剤組成物を住環境における真菌汚染の予防又は改善用途に使用する場合、本発明の抗真菌剤組成物を、スプレー剤、エアゾール剤等の形態で提供すればよい。 Further, when the antifungal agent composition of the present invention is used for the prevention or improvement of fungal contamination in a living environment, the site where fungal contamination is likely to occur, for example, the wall surface or floor surface of a kitchen, bathroom, toilet, wash basin, etc. The antifungal composition of the present invention is applied, sprayed, etc. to the drain port, washing tub, clothing, curtain, bath mat, inside of air conditioner, filter, etc. before or after fungal contamination occurs. It may be used by doing so. When the antifungal agent composition of the present invention is used for the prevention or improvement of fungal contamination in a living environment, the antifungal agent composition of the present invention may be provided in the form of a spray agent, an aerosol agent or the like.
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to these Examples.
試験例１
１．フィブロインの調製
家蚕の繭糸を４重量％炭酸水素ナトリウム水溶液に入れて１時間煮沸して精錬し、セリシンを除去してフィブロイン繊維を製造した。
Test Example 1
1. 1. Preparation of fibroin The cocoon thread of the silk moth was placed in a 4 wt% aqueous sodium hydrogen carbonate solution, boiled for 1 hour and refined, and sericin was removed to produce fibroin fiber.
次いで、６５ｇの塩化カルシウムと６０ｍＬのイオン交換水とを入れたビーカーに、前記で得られたフィブロイン繊維２．５ｇを加え、グラスウール付きの金網を使用したガスバーナーで５分間加熱処理することによりフィブロイン繊維を完全に溶解した。これをセルロース製の透析膜（輸入販売元：エーディア株式会社、製品番号UC36-32-100、分画分子量MWCOは14,000）に入れて２日間水道水で置換した後、更にイオン交換水で１日間置換した。透析膜内に残ったフィブロイン水溶液にイオン交換水を加えることで、０．５重量％の濃度のフィブロイン水溶液を得た。 Next, 2.5 g of the fibroin fiber obtained above was added to a beaker containing 65 g of calcium chloride and 60 mL of ion-exchanged water, and the fibroin was heat-treated with a gas burner using a wire mesh with glass wool for 5 minutes. The fibers were completely dissolved. This is placed in a cellulose dialysis membrane (importer / distributor: EIDIA Co., Ltd., product number UC36-32-100, molecular weight cut-off MWCO is 14,000), replaced with tap water for 2 days, and then with ion-exchanged water for 1 day. Replaced. By adding ion-exchanged water to the fibroin aqueous solution remaining in the dialysis membrane, a fibroin aqueous solution having a concentration of 0.5% by weight was obtained.
得られたフィブロイン水溶液を−５０℃で予備凍結した後に、凍結乾燥を行うことにより、フィブロインの固形物を得た。得られた固形物を粉砕することにより、フィブロインを得た。斯くして得られたフィブロインを後述する抗真菌剤組成物の調製及び抗真菌力試験に使用した。 The obtained aqueous fibroin solution was pre-frozen at −50 ° C. and then freeze-dried to obtain a solid fibroin. Fibroin was obtained by pulverizing the obtained solid matter. The fibroin thus obtained was used for the preparation of an antifungal agent composition described later and the antifungal activity test.
２．ホロトキシンの調製
ナマコの体壁組織からホロトキシンを抽出して精製し、後述する抗真菌剤組成物の調製及び抗真菌力試験に使用した。
2. Preparation of Holotoxin Holotoxin was extracted from the body wall tissue of sea cucumber, purified, and used for the preparation of an antifungal agent composition described later and the antifungal activity test.
３．抗真菌剤組成物の調製及び抗真菌力試験
表１に示す抗真菌剤組成物を調製し、以下に示す手順でハロー法による抗真菌力試験を行った。白癬菌（Trichophyton rubrum）の胞子液を作製し、ポテトデキストロース寒天培地（日水製薬株式会社）に播種した。次いで、各抗真菌剤組成物０．１ｍｌを含浸させたペーパーディスク（直径８ｍｍ）を、前記培地の中心部に置いて、３０℃で７日間培養を行った。７日間の培養後に、白癬菌が生育していない阻止帯の直径を測定した。
3. 3. Preparation of antifungal agent composition and antifungal activity test The antifungal agent composition shown in Table 1 was prepared, and the antifungal activity test was performed by the halo method according to the procedure shown below. A spore solution of Trichophyton rubrum was prepared and seeded on a potato dextrose agar medium (Nissui Pharmaceutical Co., Ltd.). Next, a paper disc (diameter 8 mm) impregnated with 0.1 ml of each antifungal agent composition was placed in the center of the medium and cultured at 30 ° C. for 7 days. After culturing for 7 days, the diameter of the inhibition zone where Trichophyton was not growing was measured.
結果を表１及び図１に示す。この結果、フィブロインには抗真菌作用を有していないにもかかわらず、フィブロインとホロトキシンを併用することにより、ホロトキシン単独の場合に比べて、格段に優れた抗真菌作用が発現されることが明らかとなった。 The results are shown in Table 1 and FIG. As a result, it is clear that, although fibroin does not have an antifungal effect, the combined use of fibroin and holotoxin exerts a significantly superior antifungal effect as compared with the case of holotoxin alone. It became.
Claims (5)
The anti-ringworm composition according to claim 1 or 2, which is used for preventing or improving ringworm contamination in a living environment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019224533A JP6902803B2 (en) | 2019-12-12 | 2019-12-12 | Antifungal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019224533A JP6902803B2 (en) | 2019-12-12 | 2019-12-12 | Antifungal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021091639A JP2021091639A (en) | 2021-06-17 |
| JP6902803B2 true JP6902803B2 (en) | 2021-07-14 |
Family
ID=76313270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019224533A Active JP6902803B2 (en) | 2019-12-12 | 2019-12-12 | Antifungal composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6902803B2 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3689735B2 (en) * | 2000-03-23 | 2005-08-31 | 独立行政法人農業生物資源研究所 | Antiviral agent |
| JP4080275B2 (en) * | 2002-08-20 | 2008-04-23 | 丸善製薬株式会社 | Antifungal agent for food |
| JP5033605B2 (en) * | 2007-12-05 | 2012-09-26 | セーレン株式会社 | Oral care composition |
| US20090162439A1 (en) * | 2007-12-22 | 2009-06-25 | University Of Louisville Research Foundation | Silk fibroin coating |
| CA2791580C (en) * | 2009-03-04 | 2017-12-05 | Trustees Of Tufts College | Silk fibroin systems for antibiotic delivery |
| JP2018087162A (en) * | 2016-11-28 | 2018-06-07 | ホロスリン製薬株式会社 | Antifungal agent |
-
2019
- 2019-12-12 JP JP2019224533A patent/JP6902803B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021091639A (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0138931B1 (en) | Dermatological composition and preparation method thereof | |
| KR20070079596A (en) | Composition of funtional cosmestic for subsidiary skin trouble treatment | |
| KR101064904B1 (en) | Cosmetic composition for improving acne comprising natural extracts | |
| KR101780863B1 (en) | Cosmetic Composion for Acne Improvement Containing Butanol Fraction of Red Ginseng Ethanol Extract | |
| KR101302678B1 (en) | Antifungal compositions containing camellia japonica extracts | |
| KR101274811B1 (en) | Potent anti-acne composition containing perilla frutescens and/or lygodium japonicum extract | |
| JP6902803B2 (en) | Antifungal composition | |
| KR100769302B1 (en) | Skin topical composition containing herbal extract for treating and improving scar pruritus | |
| JP4546790B2 (en) | Lower fatty acid production inhibitor that does not sterilize skin resident bacteria | |
| CN105520869B (en) | Composition containing Ginseng radix Rubri concentrate for improving acne | |
| JP2008184439A (en) | External preparation for skin for ameliorating cytotoxicity of active oxygen species | |
| KR102033073B1 (en) | Compositions for skin regeneration, skin soothing or wound healing comprising sericin, extracts of erect hedge parsley extract and extracts of mistletoe | |
| KR100564225B1 (en) | Athlete's foot, eczema prevention and treatment composition containing sagan, cheongpi, fat milk, casualty, Schisandra chinensis extract | |
| JP5072300B2 (en) | Cyclic AMP phosphodiesterase inhibitor | |
| KR101817318B1 (en) | Composition for inhibiting body odor using Rheum undulatus L. extract or its fraction | |
| KR100807842B1 (en) | Anti-fungal composition for deodorization | |
| KR100467022B1 (en) | Cosmetic soap composition | |
| CN107669586B (en) | Pure natural underarm odor removing cream and preparation method and application thereof | |
| KR20180137151A (en) | Cosmetic composition for preventing photo aging comprising Curcuma longa Linne leaf and Hibiscus manihot extracts | |
| KR102097775B1 (en) | Ainsliaea acerifolia extract with improved skin regeneration effect through plasma treatment and uses thereof | |
| KR20180055137A (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| KR102002169B1 (en) | Cosmetic composition for improving skin wrinkle or skin moisturizing comprising Allomyrina dichotoma larva extract as effective component | |
| JP2012025777A (en) | Vascularization inhibitor and external preparation | |
| KR101816816B1 (en) | Compositions for Angiogenesis, Skin Whitening and Anti-inflammatory Containing Lonicerae Flos Extract | |
| KR102014102B1 (en) | Composition for Improving Skin Beauty Comprising Mesquite Honey |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210324 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210615 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6902803 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |